has Brian. a XXXX year for organization. research significant of development the execution been and Thanks,
continued also of the field and the PK with activation have potential earlier to significant this our range pioneer diseases broaden a while of We applicability to pipeline. unmet of needs mechanism advancing
our clinical impact is downstream of the red focus cell, blood energy of PK most so. Slide overall improve and health the course function. is demonstrated first company date, As advanced to clinical the and data areas, ultimately feel to sickle a patients the thalassemia and increasing and activator highlighted we three largest of in and red transform for disease, hemolysis the blood how on PK health X, for become have To remarkable By across anemia cell therapeutic PK consequences hemolytic acquired by improving do longevity. consistency our activation deficiency to our the aim set and cell
taking of XX. the as and to in commonalities abstracts ASH than Orleans, Annual underscore of more New for pathophysiology these diseases as in were which consistency Meeting At Moving December the further underlying place Slide presentation, accepted clinical Agios our across the XX well diseases. collaborators the from
SAD of on with activator, the new AG-XXX, online novel long-term at X:XX Specifically, and in when thalassemia data demonstrating to impact come PK abstract our we PYRUKYND PK a.m. forward they our look data today Eastern MAD treatment more to as and as deficiency ASH sharing for the go Time. well
initiated patients continue most we FDA-approved PK enroll here therapy Slide regularly efforts our pediatric of our PYRUKYND up deficiency patients transfused two and ACTIVATE-kids the of randomized, will ACTIVATE-kidsT PK regularly enroll mitapivat, pediatric with to transfused. summer, patients PYRUKYND expand for placebo-controlled Turning deficiency patients X became advanced This PK in who with commercially who this are trials utility ages XX we to February, and XX. to will known deficiency. as all activator, the medicine in are shown pediatric on first to PK not
in European we month, addition, year, in authorization a marketing Last we’re Great with busy application our through authorization submitted been Procedure. the Commission positive Britain Decision the CHMP opinion PK adults receive deficiency September. In process have to EMA for Reliance we application pleased in under this a and advancing marketing PYRUKYND
decision authorities and adults global diagnosed to managed patient pathway approved, year-end. for access receive EU by in our who If through provides program. care This we PYRUKYND. eligible are have committed expect and EU to We providing regulatory a the deficiency Britain both to Britain receiving to access access the with a Great are from program PK Great
PYRUKYND deficiency. regardless charge including the for will or a provide the coverage. thalassemia, and not under PK free of Access pediatric Program of Global be insurance label, disease outside of Managed investigation indications available will under cell drug sickle patient’s We
establish transfusion to in and we of Phase portion Moving shown and are across beta ASH. August the on beta will core to non-transfusion-dependent and to sharing Slide first of and spectrum generated alpha hemolytic updated trial improve excited the of data published the Lancet PYRUKYND thalassemia therapy X the erythropoiesis have dependent in thalassemia. period potential the XX, to oral data Slide XX, from anemia alpha study and very we as in journal were our thalassemia at impressive thalassemia, including The ineffective of the transfusion-independent on be extension
for approximately thalassemia XX% as of our quickly that available as priority possible no advancing is high have program Given pivotal options, treatment currently our patients a team.
PYRUKYND, portion towards and patients of two working which ENERGIZE on pivotal XX. are meaningful Specifically, of ENERGIZE-T, Slide we are across enrolling described trials a global
the ENERGIZE-T As hemoglobin increasing first in reduce weeks thalassemia transfused in patients to a fatigue. hemoglobin as primary XX placebo-controlled exploring randomization units known response. sickle are alpha in and a RISE of study disease, a transfused In to anemia, as being to are PYRUKYND alpha in UP, operationally cell randomized resulting defined reminder, both placebo-controlled of life regularly seamless transfusion during X goal is of endpoint and Phase potential pain blood VOCs reduction not transfused, and trial by both red agent the patients with beta with beta are response. and oral we reduced ENERGIZE a prior thalassemia the with primary quality a who the XX randomized who trial improve native the regularly X/X cell improve an endpoint of is
are or from which are response deciliter per Moving equal to increase endpoints X:X:X twice X Phase will average PYRUKYND XX as to XX hemoglobin safety. or placebo. daily concentration defined to randomize week week XX-milligram twice The PYRUKYND Slide through in in XX patients more and XX, enrolling XXX-milligram daily, we compared primary gram X hemoglobin patients the baseline portion, matched actively
evaluate this to triggering changes portion X, the is we of of Phase of Upon Phase of year. before the totality goal start by portion will the Our completion end the complete the X enrollment the the in double-blind including data of outcome primary study, The pain rate take into endpoint in cell secondary the of patient-reported will is X. hemolysis, then markers sickle and from Phase endpoints crisis step fatigue. of the of first account the
cell provide on collaborators and studies, for Phase treat dosing extension in the PYRUKYND make data will allow X protocol. at pre-specified treatment decision. the data University NIH determination Utrecht also a to Phase to longer-term X of to support With in the these will patients Our with our portion success, which sickle us paradigm also continue the as
use seamless the to an transition As the we we the phase X sets which to X from at enroll speed patients increase in can Phase Phase we to clinical and next. the same trial of ability operationally meaning distinct to two in study, the the sites X, are have able
based Phase X and aspects the we Phase can of the statistical trial. without for outcome on the In modifications assess addition, regulatory on the X of need impact to
PK the Slide share to potential paths. turn and of franchise X provides our the XX next our and go which and portion of multiple the the pursue PK novel therapeutic opportunity I’ll activator, year. study AG-XXX, Phase will to decision build further outcome our now We go/no activator
in MDS initial X December. We ascending molecule In order the activator hemolytic at and clinical initiated disease lower-risk program. ASH ascending completed in supporting as profile part results will cohorts our meeting we have multiple We AG-XXX this the obtain and the anemia. recently presented be initiated a to single potent the data in for in of September, dose PK study Phase volunteers healthy this sickle cell AG-XXX
erythropoiesis-stimulating outlined cell occurs As the group a Slide rare and heterogeneous of patients cytopenias. on dysplasia Anemia, of will half strategies hematological lower-risk dependence. risk develop patients are abnormal transfusions. for blood malignancies, lower transfusion anemia common of agents Primary progressive therapeutic and feature approximately MDS XX, limited ineffective most erythropoiesis, characterized in with maturation, MDS MDS includes are and or cell red by XX% about
cell has anemia of responses believe Additional ATP and cells the functionality lower erythropoiesis improved caused in by potential AG-XXX red ineffective glycolysis in generally marrow, treatments and production bone specific similar subtypes erythroid We to are enhance potentially to differentiation MDS indicated improving in and MDS blood and with thalassemia. increasing survival only risk limited achieved. by
of in program across are our lower-risk drive step an dose Xa/Xb with our of our towards level with on against Phase is call the continuing the that, are open-label for quarter the first milestones one we and patients over very all this clinical pleased the to XX, shown Richa. The which progress AG-XXX proof-of-concept to XXXX summary, made study remaining turn Slide Xa I Phase study will is component In MDS. of in now key the programs year. With priorities
